Pulmatrix, Inc. (PULM) Stock Price & Analysis
Pulmatrix, Inc. (PULM) fell 2.82% to USD 1.38 as of June 10, 2026 at 03:40 UTC, according to Nexqual real-time market data.
PULM last closed at USD 1.42; the session ranged USD 1.28–1.43 on volume of 44,775 shares. Market capitalization is $5.04M, with a 52-week range of USD 1.16–9.15 (NCM). Source: Nexqual, June 10, 2026 at 03:40 UTC.
Key Statistics (as of June 10, 2026 at 03:40 UTC)
| Price | USD 1.38 |
|---|---|
| Change | ▼ 2.82% (down) |
| Previous Close | USD 1.42 |
| Open | USD 1.43 |
| Day Range | USD 1.28 – 1.43 |
| 52-Week Range | USD 1.16 – 9.15 |
| Volume | 44,775 shares |
| Market Cap | $5.04M |
| Exchange | NCM |
Technical Analysis (PULM)
Nexqual's technical model rates PULM "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:40 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 53.58 (neutral) |
| vs SMA50 | Above (USD 1.3) |
| MACD | 0 (positive) |
Analyst Ratings (PULM)
Wall Street analysts rate PULM "None", per Nexqual as of June 10, 2026 at 03:40 UTC.
| Consensus Rating | None |
|---|
Earnings (PULM)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -1.03 vs est -1.05 ▲ beat |
| 2023-06-30 | USD -1.04 vs est -1.23 ▲ beat |
| 2022-12-31 | USD -1.14 vs est -1.44 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financials & Fundamentals (PULM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -84.30% |
| Current Ratio | 4.96 |
| Total Cash | $3.32M |
| Total Debt | $0 |
| Free Cash Flow | $-3.69M |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Financial Health Score (PULM)
Nexqual rates Pulmatrix, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:40 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -84%, ROA -46.0% |
Ownership (PULM)
| Insider Ownership | +0.74% |
|---|---|
| Institutional Ownership | +9.02% |
| Shares Outstanding | 3.65M |
| Float | 3.65M |
| Short % of Float | +0.69% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
Leadership (PULM)
Pulmatrix, Inc. is led by Peter Ludlum CMA (age 70), Interim CEO & Interim CFO, per Nexqual as of June 10, 2026 at 03:40 UTC.
| Interim CEO & Interim CFO | Peter Ludlum CMA (age 70) |
|---|
Major Backers & Investors (PULM)
Notable institutional backers of Pulmatrix, Inc. include Renaissance Technologies, Fidelity, SBI Securities Co., Ltd., according to Nexqual as of June 10, 2026 at 03:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 2.99% |
| Fidelity | 1.02% |
| SBI Securities Co., Ltd. | 0.82% |
| Jane Street Group, LLC | 0.4% |
| Xtx Topco Ltd | 0.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.24% |
| BlackRock | 1.5% |
| Geode Capital | 1.22% |
| State Street | 0.38% |
| Dimensional Fund Advisors | 0.14% |
Source: Nexqual, June 10, 2026 at 03:40 UTC.
From Pulmatrix, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States.
- The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
- It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
- It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDXG | Interpace Biosciences, Inc. | USD 1.74 | ▲ 4.19% |
| BNTC | Benitec Biopharma Inc. | USD 10.81 | ▲ 2.46% |
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| MBRX | Moleculin Biotech, Inc. | USD 2.41 | ▲ 0.42% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.36 | ▼ 8.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:40 UTC. This page is informational and not investment advice.